LL-37
Cathelicidin Antimicrobial Peptide LL-37
LL-37 is an emerging peptide profile for immune health with an evidence-first safety frame.
Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptides discussed may be research compounds not approved for human use. Always consult a qualified healthcare provider before starting any peptide protocol. Read our full disclaimer →
Quick Reference
| Peptide Class | Antimicrobial Host Defense Peptide |
| Half-Life | Variable; protocol-dependent |
| Administration | Subcutaneous injection, Oral or topical where applicable |
| Typical Dosage | Protocol-dependent; discuss with a qualified clinician |
| Cycle Length | 4-12 weeks depending on goal and supervision |
| Evidence Level | Moderate Preclinical / Emerging Human |
| Legal Status | Research compound or prescription-only depending on jurisdiction and indication |
| Approximate Cost | $50-$300/month depending on source and protocol |
How LL-37 Works
LL-37 is discussed for immune health because its mechanism overlaps with immune-support, inflammation goals.
LL-37 works through pathways relevant to immune health, but it should not be treated as a universal shortcut. Research discussions focus on receptor signaling, mitochondrial function, inflammatory modulation, or metabolic regulation depending on the compound.
Evidence Base
Preclinical Evidence
Preclinical evidence suggests biologic plausibility, especially in models relevant to inflammation, metabolism, mitochondrial function, or tissue signaling.
Human Evidence
Human evidence varies by compound. Some agents have clinical trial data or approved indications; others remain early-stage research tools with limited published human outcomes.
Anecdotal Evidence
Anecdotal reports around LL-37 often focus on immune health outcomes, but user reports are highly confounded by lifestyle, dosing, concurrent protocols, and product quality.
Key PubMed References:
Safety Profile
Side Effects
Potential side effects depend on dose, route, sterility, product quality, and individual medical history. Injection-site irritation, nausea, fatigue, appetite changes, or immune effects may occur depending on compound class.
Contraindications
Avoid unsupervised use during pregnancy or breastfeeding, in active cancer, uncontrolled endocrine disease, or complex autoimmune disease unless specifically supervised by a qualified clinician.
PeptidePilot Assessment
PeptidePilot treats LL-37 as an educational profile rather than a default recommendation. It may be relevant for users whose goals align with immune-support, inflammation, but evidence level and safety context should determine whether it belongs in a real protocol discussion.
📊 Emerging profile; not yet a primary PeptidePilot algorithm match for most users.
Frequently Asked Questions
Explore More Peptides
The most researched healing peptide for joints, tendons, and gut tissue.
Systemic tissue repair and anti-inflammatory recovery for athletes and injury rehabilitation.
The cleanest growth hormone secretagogue for muscle growth, fat loss, and sleep quality.
Extended-release GHRH analogue that amplifies and sustains growth hormone pulses.
The clinically established GHRH analogue with the longest safety record in anti-aging medicine.
The most clinically validated peptide for weight loss and metabolic health.